ライフサイエンスコーパス: coronary disease

1 stem who underwent CABG or PCI for new onset coronary disease.

2 rative ischemia), and none had flow-limiting coronary disease.

3 g the highest-risk patients with more active coronary disease.

4 (n=9) secondary to KD as the cause of their coronary disease.

5 ardial infarction and those with more stable coronary disease.

6 s on development of clinical atherosclerotic coronary disease.

7 declines in older individuals and those with coronary disease.

8 eloperoxidase (MPO) has been linked to acute coronary disease.

9 atomic and functional investigation of early coronary disease.

10 and function, independent of hypertension or coronary disease.

11 scular death in patients with stable chronic coronary disease.

12 rt failure, myocardial infarction, and fatal coronary disease.

13 o more than 13% of the total heritability of coronary disease.

14 management of coexisting severe carotid and coronary disease.

15 isease (CVD) in populations with established coronary disease.

16 oronary intervention in patients with stable coronary disease.

17 ns known to affect survival in patients with coronary disease.

18 e left ventricular dysfunction and extensive coronary disease.

19 ndary prevention among patients with chronic coronary disease.

20 hy individuals and patients with established coronary disease.

21 ) are alternative treatments for multivessel coronary disease.

22 ients undergoing angiography had obstructive coronary disease.

23 meric scaffolds for treatment of obstructive coronary disease.

24 nts with type 2 diabetes mellitus and stable coronary disease.

25 133 (76%) of 175 of patients with no to mild coronary disease.

26 diography and catheterization excluded acute coronary disease.

27 recruited on the basis of family history of coronary disease.

28 llele of the same SNP with increased risk of coronary disease.

29 onstrated the ability to slow progression of coronary disease.

30 ype 1 diabetes who have an increased rate of coronary disease.

31 The Framingham equations predict incident coronary disease.

32 iovascular events among patients with stable coronary disease.

33 propriate management of patients with stable coronary disease.

34 EF) influence the prognosis of patients with coronary disease.

35 ng cardiovascular risk scales and predicting coronary disease.

36 re less likely to have a parental history of coronary disease.

37 ase and more likely to suffer mortality from coronary disease.

38 1-codon25 high-production is associated with coronary disease.

39 e the risk of stroke in patients with stable coronary disease.

40 to CABG in selected patients with left main coronary disease.

41 table, higher-risk clinical presentations of coronary disease.

42 clinical factors and angiographic extent of coronary disease.

43 among women with stable angina and confirmed coronary disease.

44 08 patients with angiographically documented coronary disease.

45 ch be moderately associated with the risk of coronary disease.

46 of viable myocardial tissue in patients with coronary disease.

47 at intermediate risk for developing clinical coronary disease.

48 rovides useful information for assessment of coronary disease.

49 lation, hypertension, diabetes mellitus, and coronary disease.

50 stable patients with symptoms suspicious for coronary disease.

51 ifying inducible ischemia due to significant coronary disease.

52 riate or uncertain indications had important coronary disease.

53 sialyltransferase and sialic acid levels and coronary disease.

54 diac Surgery) score quantifies the extent of coronary disease.

55 sured in 216 stenoses from 186 patients with coronary disease.

56 and assessment of patients with symptomatic coronary disease.

57 tensive validation as a prognostic marker in coronary disease.

58 an CTA or PET in the evaluation of suspected coronary disease.

59 among individual circulating fatty acids and coronary disease.

60 eading to altered vascular effects of HDL in coronary disease.

61 tory diseases, including atherosclerosis and coronary disease.

62 ar events in patients with clinically stable coronary disease.

63 ardiovascular events in patients with stable coronary disease.

64 ve clinical outcomes in patients with stable coronary disease.

65 rategy in patients with diabetes with severe coronary disease.

66 0.0284] and 0.0109 [0.0059-0.0159]) than for coronary disease (0.0048 [0.0029-0.0067] and 0.0036 [0.0

67 l coronaries had higher rates of obstructive coronary disease (59.2% vs. 51.3% vs. 52.6% vs. 44.3%; p

68 Groups were similar with regard to coronary disease (68%), gender (21% female), and New Yor

69 The clinical presentations were stable coronary disease (69%) and acute coronary syndromes (31%

70 P<0.001), and a higher rate of detection of coronary disease (9.0% vs. 3.5%; difference, 5.6 percent

71 o-controlled trial, 300 patients with stable coronary disease, a positive exercise treadmill test, 48

72 consider 2 broad categories of patients with coronary disease: acute and stable.

73 The extent of coronary disease affects clinical outcomes and may predi

74 We pooled individuals without pre-existing coronary disease age 45 to 74 years from the ARIC (Ather

75 9.8 years) with ejection fraction </=35% and coronary disease amenable to CABG were randomized to CAB

76 Stable patients with coronary disease and > or =3 anginal attacks per week de

77 e was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but

78 persistent chest pain include microvascular coronary disease and abnormal cardiac nociception.

79 ls incorporated traditional risk factors for coronary disease and CAC scores.

80 ve agents for the diagnoses of microvascular coronary disease and can be a useful tool to differentia

81 tically for detecting increasing severity of coronary disease and clinical events.

82 ls incorporated traditional risk factors for coronary disease and coronary artery calcification (CAC)

83 Coronary disease and diabetes mellitus had been diagnose

84 th and total mortality risk in patients with coronary disease and left ventricular dysfunction.

85 that AA are less likely to have obstructive coronary disease and more likely to suffer mortality fro

86 ified variants were strongly associated with coronary disease and myocardial infarction.

87 with single-vessel left anterior descending coronary disease and normal ventricular function (n=13)

88 trial, in which patients with chronic stable coronary disease and preserved systolic function were ra

89 From 12 patients with coronary disease and recurrent ventricular tachycardia u

90 We projected coronary disease and stroke deaths to 2030, first on the

91 addressing the 'inflammation hypothesis' in coronary disease and stroke.

92 e general population and in those with known coronary disease and to exclude low-risk patients.

93 lar morbidity and mortality in patients with coronary disease and type 2 diabetes mellitus.

94 August 2003-March 2006) in 543 patients with coronary disease and type 2 diabetes.

95 diabetes mellitus, 62.7% hypertension, 7.1% coronary disease, and 2.8% with known HF.

96 re, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic gangrene.

97 , abnormal ventricular function, severity of coronary disease, and diabetes.

98 for age, sex, body mass index, hypertension, coronary disease, and echocardiographic parameters (HR:

99 ssion independent of age, sex, hypertension, coronary disease, and ejection fraction.

100 of incident myocardial infarction and fatal coronary disease, and evaluated discriminative and calib

101 associated with cardiovascular risk factors, coronary disease, and events.

102 a-blockers were younger, more likely to have coronary disease, and had a greater mean ejection fracti

103 adjusted for age, sex, atrial fibrillation, coronary disease, and LVAD type as time-dependent Cox pr

104 women, younger patients, individuals without coronary disease, and those treated with evidence-based

105 uses, cardiovascular diseases, hypertension, coronary diseases, and stroke, respectively.

106 If advances in coronary disease are to occur, it is important to recogn

107 graphy can definitively establish or exclude coronary disease as the cause of chest pain.

108 SCT alone immediately excluded or identified coronary disease as the source of chest pain in 75% of p

109 e normal coronary arteries or nonsignificant coronary disease at coronary angiography (CA).

110 scular ultrasonography in 1039 patients with coronary disease, at baseline and after 104 weeks of tre

111 pairment (ejection fraction <30%) and severe coronary disease (BCIS-1 jeopardy score >/=8; maximum po

112 V event reduction among 15,056 patients with coronary disease but without diabetes at baseline in the

113 dard of treatment for 3-vessel and left main coronary disease, but is associated with an increased ri

114 Dyslipidemia is a known risk factor for coronary disease, but its role in heart failure (HF) dev

115 gative predictive value for the detection of coronary disease, but its usefulness in determining whet

116 ty is associated with a reduced incidence of coronary disease, but the mechanisms mediating this effe

117 (58% versus 37%; P<0.0001), less obstructive coronary disease by CCTA (5% versus 17%; P=0.0001), but

118 Young women presenting with AMI may develop coronary disease by different mechanisms and often have

119 otic cores, the substrate for acute unstable coronary disease by recruiting and activating leukocytes

120 e of ventricular arrhythmia in patients with coronary disease (CAD) receiving implantable cardioverte

121 GPIIIa C1565T), involving a total of 66 155 coronary disease cases and 91 307 controls.

122 ble evidence on each comprises at least 5000 coronary disease cases and at least 5000 controls.

123 Some coronary disease common variants show allelic heterogene

124 A heart-team approach should evaluate coronary disease complexity, patient comorbidities, pati

125 one for acute coronary syndrome and anatomic coronary disease confirmed, the benefits and risks of in

126 For patients with acute coronary disease, coronary physiology may potentially re

127 cal Subject Headings cardiovascular disease, coronary disease, coronary thrombosis, myocardial ischem

128 ass III to IV symptoms, atrial fibrillation, coronary disease, creatinine, and comorbidity index were

129 Thus, risk of sudden death in patients with coronary disease depends on multiple variables in additi

130 inflammation who are at a high risk of acute coronary disease despite a suppressive antiretroviral th

131 is neutral or beneficial for weight control, coronary disease, diabetes, hypertension, and most cance

132 beverage intake with risk of mortality from coronary diseases, diabetes, or cancer, but few studies

133 gment elevation MI found to have significant coronary disease during catheterization and who survived

134 rding to clinical factors, such as extent of coronary disease, ejection fraction, or previous procedu

135 on with unprotected left main or multivessel coronary disease, even after adjustment for known risk f

136 rdiac disease and with new heart failure and coronary disease events, but not with carotid intima-med

137 aphy-derived coronary calcium score predicts coronary disease events.

138 atients with myocardial damage on DE-CMR had coronary disease excluded by x-ray angiography.

139 non-ST-segment elevation MI with significant coronary disease face high long-term risks for mortality

140 The rate of obstructive coronary disease found at elective coronary angiography

141 Patients with coronary disease from 25 US cardiology outpatient practi

142 try (ACC-NCDR) records with 2- and 3- vessel coronary disease from 54 sites in 2004 to 2007.

143 g had an acceptable value for discriminating coronary disease from normal condition with optimal cuto

144 with the lowest ranged from 1.59 to 4.90 for coronary disease, from 1.19 to 2.69 for stroke, and from

145 essment and at 1 year, even in those in whom coronary disease had been confirmed.

146 During global ischemia, hearts with coronary disease had shorter time to enter into rigor an

147 Differences in coronary disease have been reported among ethnic minorit

148 One third of patients with significant coronary disease have chronic total coronary occlusion (

149 thrombosis, but studies of such variants in coronary disease have reported apparently conflicting re

150 followed for 13.6 +/- 3.2 years for incident coronary disease, heart failure, and CV and all-cause mo

151 ion of selected patients suspected of having coronary disease; however, in addition to coronary asses

152 e presence of significant moderate-to-severe coronary disease in 11% (22 of 197) of patients, and pre

153 nary angiography have found less obstructive coronary disease in AA than clinically similar whites.

154 Detection of occlusive coronary disease in heart transplant recipients with ele

155 properties in vitro, but its relationship to coronary disease in humans is unclear.

156 f this mouse model to the immunopathology of coronary disease in KD.

157 who underwent isolated CABG for multivessel coronary disease in New York.

158 dictors, after revascularization for complex coronary disease in patients.

159 ms on the development of acute rejection and coronary disease in pediatric heart transplant recipient

160 alue, 16-row MDCT may be useful in excluding coronary disease in selected patients in whom a false-po

161 This verified the significantly increased coronary disease in the non-synonymous dysfunctional var

162 sfunction as a precursor of clinically overt coronary disease in this specific risk group.

163 of age, with an emphasis on atherosclerotic coronary disease in those >/= 35 years of age.

164 raphy (MDCT) may be able to detect occlusive coronary disease in transplanted hearts.

165 type 2 diabetes mellitus and stable ischemic coronary disease in whom angina symptoms are controlled,

166 e) and ischaemic (ie, due to consequences of coronary disease) in developed countries, or rheumatic (

167 statins) can restore endothelial function in coronary disease, in vitro and murine studies have shown

168 A total of 10,001 patients with documented coronary disease, including 4,654 with previous CABG, we

169 icardial Diseases, Congenital Heart Disease, Coronary Disease & Interventions, and CVD Prevention & H

170 icardial Diseases, Congenital Heart Disease, Coronary Disease & Interventions, and CVD Prevention & H

171 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, CVD Prevention & Healt

172 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, CVD Prevention & Healt

173 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, Genetics, Omics, & Tis

174 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, Genetics, Omics, & Tis

175 reserved for those patients with significant coronary disease irrespective of symptoms.

176 management of concurrent severe carotid and coronary disease is a subject of ongoing debate in the a

177 A GRS composed of 13 SNPs associated with coronary disease is an independent predictor of cardiova

178 Microvascular coronary disease is associated with an increased risk of

179 ractice, survival for patients with 3-vessel coronary disease is better after CABG than PCI, an obser

180 multivessel CAD, or LVD, if the severity of coronary disease is deemed to be complex (SYNTAX >22) du

181 rapy, with initiation recommended as soon as coronary disease is documented.

182 In cases in which coronary disease is less complex (SYNTAX </=22) and/or t

183 The burden of coronary disease is lower in Mexican-American than in wh

184 ry intervention in patients with multivessel coronary disease is one of those rare situations in whic

185 s a risk of myocardial infarction unless his coronary disease is treated effectively before surgery.

186 t other risks and benefits of treatment, but coronary disease is typically not a major factor in the

187 S) is widely used to detect early transplant coronary disease, its prognostic significance has not be

188 (ejection fraction < or = 30%) and extensive coronary disease (Jeopardy Score > or = 8/12); those wit

189 operated patients, and comorbidities such as coronary disease, left heart failure, and chronic obstru

190 ned down for SL HT for reasons that included coronary disease, left ventricular dysfunction or hypert

191 The treating physicians' estimates of coronary disease likelihood were similar for AA (79.5%)

192 If we are to eliminate coronary disease, lowering LDL should be the primary goa

193 tients without MI and with low likelihood of coronary disease (lowest Framingham risk category; n=103

194 with coronary bypass surgery for multivessel coronary disease mandate that surgeons reevaluate best p

195 can occur due to apical ballooning syndrome, coronary disease, medications, volume depletion, and val

196 d its use as a marker of risk for structural coronary disease, myocardial infarction, and cerebral va

197 291 patients presenting with acute or stable coronary disease needing stents >/=3.0 mm in diameter be

198 pertrophic cardiomyopathy or atherosclerotic coronary disease, occurs primarily among male marathon p

199 t associated with risk markers, angiographic coronary disease (odds ratio, 1.03; 95% confidence inter

200 riant yielded a per-allele relative risk for coronary disease of 1.06 (1.02-1.10), but there was an i

201 dies, the per-allele relative risks (RR) for coronary disease of factor V 1691A and of prothrombin 20

202 normalities, most frequently atherosclerotic coronary disease or cardiomyopathy.

203 ions and anatomy and PCI in less complicated coronary disease or deemed a high surgical risk.

204 men (mean age 60 years) without a history of coronary disease or diabetes at baseline from the Normat

205 erences in the rates of infection, allograft coronary disease, or malignancy, but seven patients deve

206 eased mortality independent of hypertension, coronary disease, or other echocardiographic parameters.

207 s were observed regardless of age, extent of coronary disease, or PCI indication.

208 0 segments without angiographically apparent coronary disease (p = 0.004, adjusted p = 0.01).

209 p = 0.05) and had significantly less severe coronary disease (p = 0.01) than whites.

210 In stable, predominantly asymptomatic coronary disease patients with a history of myocardial i

211 ASTEROID treated 507 coronary disease patients with rosuvastatin 40 mg/d for

212 ured by quantitative coronary angiography in coronary disease patients.

213 dent predictors of atherosclerotic burden in coronary disease patients.

214 -C increases, can regress atherosclerosis in coronary disease patients.

215 medical versus invasive management of stable coronary disease, patients living in high-diagnostic-int

216 n patients matched for pretest likelihood of coronary disease (pCAD).

217 nary disease status (adjusted odds ratio for coronary disease per 1-SD increase in efflux capacity, 0

218 In patients with stable coronary disease, physiology (FFR) is a more important d

219 (median follow-up 2.5 years) with suspected coronary disease, plasma levels of 53 previously reporte

220 We review the genetics of CETP and coronary disease, preclinical data on CETP inhibition an

221 mic circumstances across a broad spectrum of coronary disease presentations, including acute coronary

222 d in the absence of a potentially lethal non-coronary disease process.

223 tions between the changes in CRP levels with coronary disease progression and MACE.

224 The effect of renin inhibition on coronary disease progression has not been investigated.

225 enic mechanisms associated with pathological coronary disease progression.

226 In patients with more extensive coronary disease, prompt CABG, in the absence of contrai

227 e rule-out protocol was used to evaluate for coronary disease, pulmonary embolism, aortic dissection,

228 osclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition

229 ical trial of patients (n=1800) with complex coronary disease randomized to revascularization with pe

230 ed endpoint design, 532 patients with stable coronary disease receiving aspirin and/or clopidogrel (9

231 essel (25% vs 28%) and 3-vessel (23% vs 26%) coronary disease, regardless of ACS type.

232 ensity-matched using demographics, extent of coronary disease, regional wall motion, and quantitative

233 For a subset of patients with left main coronary disease, registry overcall was not linked to in

234 ch to managing coexisting severe carotid and coronary disease remains uncertain.

235 atients with any VHD had more heart failure, coronary disease, renal impairment, and persistent atria

236 oronary artery bypass graft) for multivessel coronary disease, repetitive transcranial magnetic stimu

237 of OMT remains low in patients with complex coronary disease requiring coronary intervention with pe

238 In heart transplant recipients, asymptomatic coronary disease requiring frequent surveillance commonl

239 tes has declined, and prevalences of several coronary disease risk factors have become comparable to

240 A total of 95% of patients had 2 or more coronary disease risk factors, and 25% had unstable symp

241 rebound to levels associated with increased coronary disease risk.

242 ed genes may also display genomic signals of coronary disease risk.

243 lial hypercholesterolaemia and patients with coronary disease secondary to raised levels of lipoprote

244 re inversely associated with patient age and coronary disease severity.

245 on the Evaluation of FFR-Guided Treatment of Coronary Disease), sharing a common design, were pooled

246 Optimal therapy for diabetic coronary disease should include a comprehensive approach

247 nt with atorvastatin in patients with stable coronary disease significantly reduces hospitalizations

248 In patients with more extensive coronary disease, similar to those enrolled in the coron

249 them for the treatment of acute and chronic coronary disease, specifically in the setting of acute c

250 x capacity was a strong inverse predictor of coronary disease status (adjusted odds ratio for coronar

251 ic; albeit, their prevalence correlated with coronary disease status (p = 0.017).

252 In patients with stable coronary disease, stenosis severity as assessed by FFR i

253 ed incidence of hypertension and, in men, of coronary disease, stroke, and heart failure.

254 Incident CVD, defined as coronary disease, stroke, or other atherosclerotic CVD d

255 Patients who present with unstable coronary disease, such as acute myocardial infarction, m

256 patients who present with relatively stable coronary disease, such as exertional angina.

257 Patients with diabetes have more extensive coronary disease than those without diabetes, resulting

258 that, among older patients with multivessel coronary disease that did not require emergency treatmen

259 ries from 43 patients with various levels of coronary disease to assess the clinical relevance of the

260 onsistently demonstrated a family history of coronary disease to be predictive for future cardiovascu

261 ar benefits of treating patients with stable coronary disease to LDL-C levels substantially below 100

262 traditional indications such as diagnosis of coronary disease to novel applications such as in congen

263 randomly assigned 2287 patients with stable coronary disease to PCI plus optimal medical therapy or

264 itus and angiographically documented, stable coronary disease to strategies of (1) prompt revasculari

265 are frequent among patients with symptomatic coronary disease treated by percutaneous coronary interv

266 Patients with multivessel coronary disease treated with coronary artery bypass gra

267 Relevance: Among patients with angiographic coronary disease treated with statins, addition of evolo

268 Among patients with established coronary disease, treating to an LDL-cholesterol substan

269 For patients with coronary disease, treatment with an ACAT inhibitor did n

270 n efficient surrogate for clinical events in coronary disease trials?

271 consecutive patients with known or suspected coronary disease undergoing exercise MPGS between 1997 a

272 raction (mean 64 +/- 5%) and no angiographic coronary disease underwent CMR (cine and delayed post-co

273 2000 and 2007, 8,837 patients with new onset coronary disease underwent initial CABG, and 14,516 unde

274 A total of 1188 patients with coronary disease underwent intravascular ultrasonography

275 5), in which 1455 patients with angiographic coronary disease underwent serial intravascular ultrason

276 have separate and opposite associations with coronary disease, using waist circumference alone may pr

277 rent effective cardiovascular treatments for coronary disease, vascular atherosclerosis, ectasia and

278 s >/=80 years of age frequently have complex coronary disease warranting DES but have a higher risk o

279 ical angina, and the pre-test probability of coronary disease was 49%.

280 Adults whose first clinical presentation of coronary disease was either acute myocardial infarction

281 The Framingham Risk Score for patients with coronary disease was used to summarize clinical risk.

282 mized, controlled trials, relative risks for coronary disease were 0.97 (CI, 0.69 to 1.36) for alpha-

283 In observational studies, relative risks for coronary disease were 1.02 (95% CI, 0.97 to 1.07) for sa

284 or echocardiographic evidence of valvular or coronary disease were age and gender matched to a refere

285 ar, p<0.0001), and the main risk factors for coronary disease were also risk factors for bleeding.

286 phic ventricular tachycardia associated with coronary disease were analyzed for cardiovascular-specif

287 Symptomatic patients without known coronary disease were enrolled into 2 strata based on wh

288 Women with confirmed coronary disease were less likely to be revascularized t

289 nterventions: Participants with angiographic coronary disease were randomized to receive monthly evol

290 Patients (n=10,001) with stable coronary disease were randomized to treatment with atorv

291 trial where 10,001 patients with documented coronary disease were randomized to treatment with atorv

292 Patients with multivessel coronary disease were recruited into a randomized trial

293 isting mitral regurgitation, and preexisting coronary disease were significant predictors of primary

294 he long-term outcome of patients with stable coronary disease when used as initial therapy.

295 n alternative option in patients with severe coronary disease who are considered 'high risk' for CEA.

296 uld provide another option for patients with coronary disease who require further reduction in LDL (l

297 hether rimonabant is useful in management of coronary disease will require additional imaging and out

298 , multicenter study of patients with FMR and coronary disease with core laboratory analysis.

299 ular events of treating patients with stable coronary disease with low-density lipoprotein cholestero

300 wed no significant overall associations with coronary disease, yielding per-allele RRs of 0.97 (0.91-